Patents Assigned to JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD.
  • Publication number: 20220274983
    Abstract: A JAK kinase inhibitor and use thereof. The JAK kinase inhibitor is a compound represented by formula (I) or a stereoisomer or tautomer thereof or a pharmaceutically acceptable salt thereof or a solvate or prodrug thereof. Further, the use of the compound of formula I in preparation of drugs for preventing or treating JAK kinase-related diseases, especially in preparation of drugs for preventing and/or treating diseases involving cartilage degradation and bone and/or joint degradation, conditions involving inflammation or immune response, endotoxin-driven disease states, cancer, and organ transplantation rejection.
    Type: Application
    Filed: August 5, 2020
    Publication date: September 1, 2022
    Applicant: JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD.
    Inventors: Yinlin QIN, Mei SU
  • Patent number: 11369589
    Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.
    Type: Grant
    Filed: January 22, 2019
    Date of Patent: June 28, 2022
    Assignees: NANJING CAREPHAR SHENGHUI PHARMACEUTICAL CO., LTD., JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD.
    Inventors: Yinlin Qin, Mei Su, Min Ji, Haidong Liu, Xi Zong, Xianzhi Wu
  • Patent number: 10913714
    Abstract: The present invention relates to a new pyrrole sulfonyl derivative, and a preparation method and medical use thereof. In particular, the present invention relates to a pyrrole sulfonyl derivative as represented by general formula (I), a preparation method thereof, a pharmaceutical composition comprising the derivative, and a use thereof as a therapeutic agent, in particular as a gastric acid secretion inhibitor and as potassium-competitive acid blockers (P-CABs), wherein each substituent group of general formula (I) is the same as that defined in the description.
    Type: Grant
    Filed: November 11, 2015
    Date of Patent: February 9, 2021
    Assignees: JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD, NANJING CAREPHAR SHENGHUI PHARMACEUTICAL CO., LTD
    Inventors: Yinlin Qin, Mei Su, Qiu Jin, Tao Chen, Jianhua Jiang
  • Publication number: 20210030723
    Abstract: The present invention relates to a modulator of 1,2,5-oxadiazole indoleamine-(2,3)-dioxygenase, a preparation method and use thereof, more particularly to compounds of Formula I and Formula II, an isomer thereof, a pharmaceutically acceptable salt or a pharmaceutically acceptable solvate thereof, and their use in preparing drugs for treating cancers, neurodegenerative diseases, eye diseases, mental disorders, depression, anxiety disorders, Alzheimer's diseases and/or autoimmune diseases. Specific meanings of R substituents in Formula I and Formula II are consistent with the description of the specification.
    Type: Application
    Filed: January 22, 2019
    Publication date: February 4, 2021
    Applicants: NANJING CAREPHAR SHENGHUI PHARMACEUTICAL CO., LTD., JIANGSU CAREPHAR PHARMACEUTICAL CO., LTD.
    Inventors: Yinlin QIN, Mei SU, Min JI, Haidong LIU, Xi ZONG, Xianzhi WU